JoyceSteinbergMD

PubMed

• Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
  Maha Hussain, Cora N Sternberg, Eleni Efstathiou, Karim Fizazi, Qi Shen, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Ugo De Giorgi, Neal D Shore, Fred Saad> ;The Journal of Urology. 2023 Mar 1
• Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
  Ugo De Giorgi, Maha Hussain, Neal Shore, Karim Fizazi, Bertrand Tombal, David Penson, Fred Saad, Eleni Efstathiou, Katarzyna Madziarska, Joyce Steinberg, Jennifer Sugg...> ;Future Oncology. 2022 Nov 1
• 11 citations
  Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibito...
  Bradley McGregor, Peter H O'Donnell, Arjun Balar, Daniel Petrylak, Jonathan Rosenberg, Evan Y Yu, David I Quinn, Elisabeth I Heath, Mary Campbell, Zsolt Hepp, Caroline...> ;European Urology. 2022 May 1
• Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
  Baek-Yeol Ryoo, Daniel H Palmer, Sook Ryun Park, Lorenza Rimassa, Debashis Sarker, Bruno Daniele, Joyce Steinberg, Beatriz López, Ho Yeong Lim> ;Clinical Drug Investigation. 2022 Mar 1
• 4 citations
  Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis...
  Ugo De Giorgi, Maha Hussain, Neal D. Shore, Karim Fizazi, Bertrand Tombal, David F. Penson, Fred Saad, Eleni Efstathiou, Katarzyna Madziarska, Joyce Steinberg, Jennife...> ;European Journal of Cancer. 2021 Nov 13
• 3 citations
  Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma
  Baek-Yeol Ryoo, Daniel H. Palmer, Sook Ryun Park, Lorenza Rimassa, Debashis Sarker, Bruno Daniele, Joyce Steinberg, Beatriz López, Ho Yeong Lim> ;Clinical Drug Investigation. 2021 Aug 5
• 97 citations
  Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
  Evan Y. Yu, Daniel P. Petrylak, Peter H. O'Donnell, Jae-Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, Andrea Necchi, Takahiro Kojima, Michael R. ...> ;The Lancet. Oncology. 2021 Jun 1
• 16 citations
  The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
  Andrew M Wardley, Javier Cortes, Louise Provencher, Kathy D. Miller, A. Jo Chien, Hope S. Rugo, Joyce Steinberg, Jennifer Sugg, Iulia Cristina Tudor, M.T. Huizing, Rob...> ;Breast Cancer Research and Treatment. 2021 Feb 16
• 9 citations
  Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Re...
  Fred Saad, Cora N. Sternberg, Eleni Efstathiou, Karim Fizazi, Katharina Modelska, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Neal D. Shore, Maha Hussain> ;European Urology. 2020 Oct 1
• 25 citations
  A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
  Ian E. Krop, Vandana G. Abramson, Marco Colleoni, Tiffany A. Traina, Frankie A. Holmes, Laura García-Estévez, Lowell L. Hart, Ahmad Awada, Claudio Zamagni, Patrick G. ...> ;Clinical Cancer Research. 2020 Sep 28
• 16 citations
  Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis...
  Andrew J. Armstrong, Mohammed Al-Adhami, Ping Lin, Teresa Parli, Jennifer Sugg, Joyce Steinberg, Bertrand Tombal, Cora N. Sternberg, Johann S. de Bono, Howard I. Scher...> ;JAMA Oncology. 2020 Feb 1
• 21 citations
  Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
  Amit M. Oza, Stanley B. Kaye, Jan M. Van Tornout, Cristiana Sessa, Martin Gore, R. Wendel Naumann, Hal W. Hirte, Nicoletta Colombo, Jihong Chen, Seema Gorla, Srinivasu...> ;Gynecologic Oncology. 2018 May 1
• Anonymous retrospective HIV tesing in Chinese patients with non-Hodgkin's lymphoma.
  Steinberg Jl, Mok Ts, Yeo W, Johnson Pj, Tam Js, Chan Pk> ;Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi. 1999 Mar 1
• 289 citations
  Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
  Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley, Janice F. Eakle, Lee S. Schwartzberg, Joyce O'Shaughnessy, William J. Gradishar, Peter Schmid, Eric P. Winer, Ca...> ;Journal of Clinical Oncology. 2018 Jan 26
• 40 citations
  A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer
  Lee S. Schwartzberg, Denise A. Yardley, Anthony D. Elias, Manish R. Patel, Patricia LoRusso, Howard A. Burris, Ayca Gucalp, Amy C. Peterson, Martha Elizabeth Blaney, J...> ;Clinical Cancer Research. 2017 Aug 1
• 26 citations
  Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal ...
  Natasha B. Leighl, Naiyer A. Rizvi, Lopes Gilberto de Lima, Wichit Arpornwirat, Charles M. Rudin, Alberto Chiappori, Myung-Ju Ahn, Laura Q.M. Chow, Lyudmila Bazhenova,...> ;Clinical Lung Cancer. 2017 Jan 1
• 30 citations
  A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma
  Kyriakos P. Papadopoulos, Javier Lopez-Jimenez, Scott E. Smith, Joyce Steinberg, Anne Keating, Carolyn Sasse, Fei Jie, Antoine Thyss> ;Leukemia & Lymphoma. 2016 Feb 9
• 36 citations
  A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma
  Ragini R. Kudchadkar, Scott Ernst, Bartosz Chmielowski, Bruce G. Redman, Joyce Steinberg, Anne Keating, Fei Jie, Caroline Chen, Rene Gonzalez, Jeffrey S. Weber> ;Cancer Medicine. 2015 May 1
• 63 citations
  Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
  Michael R. Clemens, Oleg Gladkov, Elaina M. Gartner, Vladimir Ivanovich Vladimirov, John Crown, Joyce Steinberg, Fei Jie, Anne Keating> ;Breast Cancer Research and Treatment. 2015 Jan 1
• 77 citations
  Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies
  Chiung-Ing Wong, Tong San Koh, Ross A. Soo, Septian Hartono, Choon Hua Thng, Evelyn McKeegan, Wei Peng Yong, Chien-Shing Chen, Soo Chin Lee, John Wong, Robert Lim, Nor...> ;Journal of Clinical Oncology. 2009 Oct 1
• ABT-869 in non-small cell lung cancer (NSCLC): Interim results.
  Tan E, Salgia R, Besse B, Goss G, Gandara DR, Hanna N, Steinberg J, Steinberg J, Qian J, Carlson DM, Soo R> ;J. Clin. Oncol.. 2009-05-20
• A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis.
  Toh H, Chen P, Carr BI, Knox JJ, Gill S, Steinberg J, Carlson DM, Qian J, Qin Q, Yong W> ;J. Clin. Oncol.. 2009-05-20
• 195 citations
  Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer†‡
  Joel B. Nelson, William Love, Joseph L. Chin, Fred Saad, Claude Schulman, Darryl J. Sleep, Jiang Qian, Joyce Steinberg, Michael A. Carducci> ;Cancer. 2008 Nov 1
• 4 citations
  Targeting the unmet medical need: the Abbott Laboratories oncology approach.
  Dawn M Carlson, Joyce L Steinberg, Gary Gordon> ;Clinical Advances in Hematology & Oncology. 2005 Sep 1
• 64 citations
  Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
  Charles M. Rudin, John L. Marshall, Chao Hui Huang, Hedy L. Kindler, Chuanbo Zhang, Deepak Kumar, Prafulla C. Gokhale, Joyce Steinberg, Steve Wanaski, Usha Kasid, Mark...> ;Clinical Cancer Research. 2004 Nov 1
• Join now to see all

Journal Articles

• A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer  
  Ian Krop, Vandana Abramson, Marco Colleoni, Tiffany Traina, Frankie Holmes, Laura Garcia-Estevez, Lowell Hart, Ahmad Awada, Claudio Zamagni, Patrick Morris, Lee Schwar..., Clinical Cancer Research, 10/2020
• Enzalutamide Survival in Nonmetastatic Castration-Resistant Prostate Cancer  
  Cora N. Sternberg, Karim Fizazi, Fred Saad, Neal D. Shore, Ugo De Giorgi, David F. Penson, Ubirajara Ferreira, Eleni Efstathiou, Katarzyna Madziarska, Michael P. Kolin..., New England Journal of Medicine, 5/29/2020